Survival in patients with rheumatoid arthritis and recently diagnosed early-stage colorectal, lung, or prostate cancer receiving tumour necrosis factor inhibitors: a retrospective cohort study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Tumor necrosis factor (TNF) inhibitors did not negatively impact survival in rheumatoid arthritis patients with early-stage colorectal, lung, or prostate cancer. This study found no significant survival differences when comparing TNF inhibitors to conventional synthetic disease-modifying antirheumatic drugs (DMARDs).
Area Of Science
- Rheumatology and Oncology
- Immunomodulatory Therapies in Cancer Patients
- Long-term Cancer Survival Outcomes
Background
- Tumor necrosis factor (TNF) inhibitors are used for rheumatoid arthritis but may affect anti-tumoral immunity.
- Investigating the impact of TNF inhibitors on cancer survival in rheumatoid arthritis patients is crucial.
Purpose Of The Study
- To assess the association between TNF inhibitor treatment and survival in rheumatoid arthritis patients diagnosed with colorectal, lung, or prostate cancer.
- To compare survival outcomes for patients treated with TNF inhibitors versus conventional synthetic disease-modifying antirheumatic drugs (DMARDs) or no DMARDs.
Main Methods
- Secondary data analysis of the Surveillance, Epidemiology, and End Results (SEER) Medicare-linked dataset (2008-2019).
- Inclusion of patients aged 66+ with early-stage colorectal, lung, or prostate cancer and rheumatoid arthritis.
- Landmark analyses at 1, 2, and 3 years post-diagnosis using propensity score-adjusted Cox regression for 5-year overall and cancer-specific survival.
Main Results
- No significant deleterious association was found between TNF inhibitor use and overall or cancer-specific survival for any of the three cancer types.
- Hazard ratios for overall survival at year 1 comparing TNF inhibitors to conventional synthetic DMARDs were consistently below 1, indicating no increased risk.
- Glucocorticoid use in the first year post-diagnosis was associated with significantly worse survival outcomes across all cancer types.
Conclusions
- Treatment with TNF inhibitors within 3 years of diagnosis for early-stage colorectal, lung, or prostate cancer is not linked to poorer survival in rheumatoid arthritis patients.
- Findings suggest TNF inhibitors can be safely used in this patient population without compromising cancer survival.
- Generalizability to other cancer types or populations may be limited.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...